1
|
Pommier RM, Morel AP, Tissier A, Thomas E, Kielbassa J, Tonon L, Sohier E, Viari A, Saintigny P, Puisieux A. Abstract P2-07-06: Multi-omics characterization of claudin-low breast tumors. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-07-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast tumors display highly heterogeneous characteristics both at transcriptional level and in term of genomic landscape. We recently reported that the differentiation status of the cell-of-origin influences the genetic route toward tumorigenesis1. Indeed, mammary stem cells exhibit the intrinsic property to tolerate the oxidative stress inherent to the oncogenic transformation through the expression of a preemptive program driven by ZEB1, an epithelial-to-mesenchymal transition (EMT)-related transcription factor, and MSRB3, a methionine sulfoxide reductase. Thereby, ZEB1-expressing tumors exhibit low level of DNA damage associated with few genomic alterations and low level of TP53 mutations. Importantly, these tumors share several transcriptional characteristics and features with normal stem cells, and with Claudin-Low (CL) molecular subtype of breast cancers. In the present work, we attempt to decipher molecular traits of CL breast tumors through multi-omics analyses of publicly available databases. This global approach allows us to highlight various CL breast tumors features as clinical attributes, gene expression, copy number alterations (CNA), somatic mutations or drug responses by differential analyses of breast tumors and cancer cell lines. Preliminary results indicate that, independently of tumor purity, CL breast tumors are mostly diploids, present a paucity of genomic rearrangements and a lower mutation rate compared to other breast tumors. They mainly, but not exclusively, show basal features and belong to the integrative cluster 4 (CNA-devoid) described by Christina Curtis and colleagues2. Concerning gene expression, CL breast tumors exhibit a frequent activation of RAS signaling pathway, an observation consistent with their sensitivity to MAPK inhibitors. Other analyses are currently ongoing and aim to better understand the biology of CL breast tumors in order to improve both the diagnosis and the therapeutic strategy used.
1. Morel A-P et al. A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nature Medicine. 2017 Apr 10.
2. Curtis C et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012 Apr 18.
Citation Format: Pommier RM, Morel A-P, Tissier A, Thomas E, Kielbassa J, Tonon L, Sohier E, Viari A, Saintigny P, Puisieux A. Multi-omics characterization of claudin-low breast tumors [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-07-06.
Collapse
Affiliation(s)
- RM Pommier
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - A-P Morel
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - A Tissier
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - E Thomas
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - J Kielbassa
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - L Tonon
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - E Sohier
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - A Viari
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - P Saintigny
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| | - A Puisieux
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue Contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France; Fondation Synergie Lyon Cancer, Plateforme de Bioinformatique Gilles Thomas, Centre Léon Bérard, Lyon, France; Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Avenue de l'Europe, Montbonnot-Saint Martin, France
| |
Collapse
|
2
|
Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier AS, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. Abstract P6-07-13: New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-07-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2-positive (HER2+) breast cancers are defined by the amplification and/or overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12. Although anti-HER2 targeted therapies have greatly improved treatment of HER2+ breast cancer, the magnitude of benefit varies widely between patients. Deciphering the genomic and genetic heterogeneity of HER2+ breast cancer may provide a basis to better understand their natural history, opening new avenues of treatment.
Methods: As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 HER2+ primary invasive carcinomas, and a genome wide association study (GWAS) of over 9.836 breast cancer patients in the prospective SIGNAL/PHARE cohort (NCT00381901 – RECF1098).
Results: Using WGS data we precisely delineate the ERBB2 amplicon as a 106 kb region involving six genes and show that the amplification mechanism was consistent with breakage-fusion-bridge (BFB) cycles. Four RNA expression-based groups were identified, displaying specific genomic alterations in terms of amplification, rearrangements and mutations. On other hand, GWAS analyses failed to identify any constitutional variants associated with HER2 amplification.
Discussion: By combining whole genome sequencing and expression analysis, we provide evidence showing that HER2+ tumours display considerably more molecular heterogeneity than previously reported. These results are reinforced with the lack of association between any genetic variants and HER2 amplification from GWAS analyses. Taken as a whole, these results suggest that HER2+ breast cancers do not represent per se a homogeneous subtype, but are distributed along the whole breast cancer spectrum, from ER-positive luminal to ER-negative basal phenotype. Genome alterations present in HER2+ tumors are in accordance with these phenotypes, and it is likely that the HER2 amplification is a secondary event in the course of tumorigenesis, not favored by any particular constitutional or somatic genetic variants.
Citation Format: Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier A-S, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-07-13.
Collapse
Affiliation(s)
- A Vincent-Salomon
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A Ferrari
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - X Pivot
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - G Macgrogan
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - L Arnould
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - I Treilleux
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - G Romieux
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A-S Sertier
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - E Thomas
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - L Tonon
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - S Boyault
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - J Kielbassa
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - V Letexier
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - I Pauporte
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - D Birbaum
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - P Saintigny
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - D Cox
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A Viari
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| |
Collapse
|